Glycemic Management and Aging in Type 2 Diabetes

As the global population ages, the management of blood glucose in individuals with type 2 diabetes demands an increasingly nuanced approach. Ageing is accompanied by changes in renal clearance, cognitive function and nutritional status, all of which alter both the risks and benefits of glycaemic control. While tight glycaemic targets can reduce microvascular complications, they may predispose older patients to hypoglycaemia, falls and cognitive decline. In contrast, more relaxed targets may be appropriate for those with limited life expectancy or significant comorbidity. The advent of novel agents such as sodium–glucose cotransporter-2 inhibitors and GLP-1 receptor agonists has shifted first-line therapy by offering cardiovascular and renal protection alongside glucose lowering. Contemporary guidelines advocate individualised haemoglobin A₁c goals, periodic re-evaluation of treatment intensity and attention to patient frailty, functional status and preferences. Integrating geriatric principles with diabetes care can optimise outcomes, reduce adverse events and support healthy ageing in this vulnerable population.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Glycemic Management and Aging in Type 2 Diabetes publication trend

The graph below shows the total number of articles in glycemic management and aging in type 2 diabetes across all publications each year (not limited to Nature Index journals).

Technical terms

Glycated haemoglobin (HbA₁c): The percentage of haemoglobin bound to glucose over the preceding two to three months, used to gauge long-term glycaemic control.

Hypoglycaemia: A condition of abnormally low blood glucose concentrations, typically below 4.0 mmol/L, which can cause cognitive impairment, falls and cardiovascular events.

SGLT2 inhibitor: A class of oral agents that reduce renal glucose reabsorption, lowering blood glucose and conferring cardiovascular and renal benefits.

GLP-1 receptor agonist: A peptide-based therapy that enhances insulin secretion, suppresses glucagon release and slows gastric emptying, with favourable effects on weight and cardiovascular risk.

Glycaemic de-intensification: The reduction or discontinuation of glucose-lowering therapy to decrease the risk of hypoglycaemia, especially in frail or elderly patients.

Frailty: A multidimensional syndrome characterised by diminished physiological reserve and increased vulnerability to stressors, often assessed by functional status and comorbidities.

References

1. Age disparities in glucose-lowering treatment for Danish people with type 2 diabetes: a cross-sectional study between 2019 and 2020. The Lancet Healthy Longevity (2023).
2. Diabetes mellitus in older persons with neurocognitive disorder: overtreatment prevalence and associated structural brain MRI findings. BMC Geriatrics (2024).
3. Deintensification of Treatment With Sulfonylurea and Insulin After Severe Hypoglycemia Among Older Adults With Diabetes. JAMA Network Open (2021).